Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Sjogren's Syndrome

Sjogren's Syndrome

Part of Arthritis

11 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Sjogren's Syndrome

23 trials tracked for Sjogren's Syndrome: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 4 citations.

23Trials tracked
2Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 2 Phase 2 18 Other / NA 3
  1. Phase 4 Nasal Spray Study in Sjogren's Dry Eye Disease Completed · 4 cited
  2. Phase 4 Assessment of Inflammatory Biomarkers Expressed in a Sjogren's Population: Effect of a Topical Steroid Intervention Completed
  3. Phase 2 Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Primary Sjögren's Syndrome Completed
  4. Phase 2 A Study to Evaluate the Efficacy and Safety of VIB4920 in Participants With Sjögren's Syndrome Completed
  5. Phase 2 Safety, Tolerability, Pharmacokinetics, and Therapeutic Efficacy of SAR441344 in Primary Sjögren's Syndrome (pSjS) Completed
  6. Phase 2 Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome Completed
Show 17 more trials
  1. Phase 2 Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis Completed
  2. Phase 2 A Study to Assess the Efficacy of RO5459072 in Participants With Primary Sjogren's Syndrome Completed
  3. Phase 2 Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients Completed
  4. Phase 2 Study of Safety and Tolerability of CFZ533 in Patients With Sjögren's Syndrome Completed
  5. Phase 2 A Study of the Safety and Effectiveness of Efgartigimod in Patients With Primary Sjögren's Syndrome (pSS) Completed
  6. Phase 2 Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome Completed
  7. Phase 2 A Phase 2a, Randomized, Placebo Controlled, Study to Evaluate the Safety and Efficacy of AMG 557/MEDI5872 in Primary Sjögren's Syndrome Completed
  8. Phase 2 A Study of INCB050465 in Primary Sjögren's Syndrome Completed
  9. Phase 2 Safety, Pharmacokinetics, and Preliminary Efficacy Study of CDZ173 in Patients With Primary Sjögren's Syndrome Completed
  10. Phase 2 PD of VAY736 in Patients With Primary Sjögren's Syndrome Completed
  11. Phase 2 Exploratory Study for Dry Mouth in Patients With Sjögren's Syndrome Completed
  12. Phase 2 Open-Label Extension Study to Evaluate the Safety of Efgartigimod in Adult Patients With Primary Sjögren's Syndrome Completed
  13. Phase 2 A Study of RSLV-132 in Subjects With Primary Sjogren's Syndrome Completed
  14. Phase 2 Comparative Study of Thymosin Beta 4 Eye Drops vs. Vehicle in the Treatment of Severe Dry Eye Completed
  15. N/A e-Mobile Tablet for People With Chronic Conditions Completed
  16. N/A TrueTear in Sjogren's Disease Patients Completed
  17. N/A Pilot Study to Investigate the Feasibility, Reliability and Efficacy of Utilizing OCT to Automate PROSE Fitting Completed

Showing the 23 most-cited and recently-updated of 23 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Sjogren's Syndrome: what the trials found

Efgartigimod shows promise in Sjögren's syndrome. In a Phase 2 trial (N=24), it led to CRESS responders and improvements in ESSDAI at weeks 24 and 48 1. Another Phase 2 trial (N=34) reported that 45.5% of patients met the overall CRESS response at week 24, and 72.7% achieved minimal clinically important improvement in ESSDAI 5. These findings are consistent and suggest efgartigimod may be effective.

Varenicline nasal spray improved eye dryness in a Phase 4 trial (N=39), with a mean change in eye dryness VAS of -14.51 2. Maxidex was studied in a Phase 4 trial (N=97) for Sjögren's syndrome 3.

Recent results — preliminary, needs further review

  • SAR441344 (Phase 2, N=84) showed changes from baseline in ESSDAI (-5.60, -5.29) and ESSPRI (-2.21, -1.92) at week 12 4.
  • Iscalimab (Phase 2, N=206) is under investigation 6.

For the clinician treating this condition

  • Efgartigimod has demonstrated efficacy in improving disease activity and patient-reported outcomes in two Phase 2 trials.
  • Varenicline nasal spray may provide symptomatic relief for dry eye in Sjögren's syndrome.
  • Recent trials with SAR441344 and iscalimab are exploring new therapeutic options.

AI synthesis of 6 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions
Allergy & Immunology Sys. Review
Genistein shows potential to attenuate inflammation and reduce disease severity in autoimmune conditions Genistein may help reduce inflammation in several autoimmune diseases
This mini review synthesizes preclinical evidence on genistein for autoimmune diseases including SLE, RA, and type 1 diabetes. Findings sugg…
A review of genistein shows it could lower disease severity and inflammation for people with conditions like lupus and rheumatoid arthritis.
Frontiers Jul 6, 2026
Narrative review discusses CD40/CD40L signaling regulation in rheumatoid arthritis and other autoimmune conditions
Allergy & Immunology Sys. Review
Narrative review discusses CD40/CD40L signaling regulation in rheumatoid arthritis and other autoimmune conditions Safer CD40/CD40L targeting needs selectivity for autoimmune diseases
This narrative review examines CD40/CD40L signaling regulation in rheumatoid arthritis, systemic lupus erythematosus, and Sjogren's syndrome…
A narrative review suggests that safer therapeutic targeting of CD40/CD40L signaling will require greater selectivity to treat rheumatoid ar…
Frontiers May 18, 2026
Systematic review explores the role of RNA methylation in autoimmune rheumatic diseases
Rheumatology Sys. Review
Systematic review explores the role of RNA methylation in autoimmune rheumatic diseases RNA Methylation Could Change How We Treat Joint Pain
This systematic review examines the impact of RNA methylation on various autoimmune rheumatic diseases, including rheumatoid arthritis and s…
A new review explains how tiny chemical tags on RNA control inflammation and could lead to better treatments for painful autoimmune diseases…
Frontiers May 2, 2026
Peripheral nerve lesion types in patients with primary Sjögren's syndrome
Neurology Cohort
Peripheral nerve lesion types in patients with primary Sjögren's syndrome Nerve damage affects many people with Sjögren's syndrome
This retrospective observational study of 92 patients with primary Sjögren's syndrome examined the clinical and serological characteristics …
New data shows that nerve issues are common in Sjögren's syndrome patients and may follow a specific pattern.
Frontiers Apr 30, 2026
Systematic review and meta-analysis of stem cell therapy for dry eye in Sjögren's syndrome
Allergy & Immunology Meta-analysis
Systematic review and meta-analysis of stem cell therapy for dry eye in Sjögren's syndrome Stem Cell Therapy Eases Dry Eye in Sjögren’s Syndrome Patients
This systematic review and meta-analysis evaluated stem cell therapy for patients with dry eye syndrome caused by Sjögren's syndrome.
New analysis shows stem cell therapy eases dry eye pain and improves tear flow for people with Sjögren’s syndrome.
Frontiers Apr 29, 2026
Anti-centromere antibody-positive Sjögren's syndrome profile predicted by serologic and clinical factors
Allergy & Immunology Cohort
Anti-centromere antibody-positive Sjögren's syndrome profile predicted by serologic and clinical factors New Tool Predicts Hidden Risk in Sjögren’s Patients
This retrospective observational cohort study developed a predictive model for anti-centromere antibody-positive Sjögren's syndrome in 616 p…
Dry eyes. Dry mouth. Fatigue. For many with Sjögren’s syndrome, these are daily struggles.
Frontiers Apr 24, 2026
Narrative review discusses screening and prevention in rheumatic and musculoskeletal disease populations
Cardiology Sys. Review
Narrative review discusses screening and prevention in rheumatic and musculoskeletal disease populations Joint Pain May Signal Hidden Risk in Your Legs
This narrative review examines patients with rheumatic and musculoskeletal diseases (RMDs), including rheumatoid arthritis and systemic lupu…
Inflammation from autoimmune conditions can silently damage blood vessels in your legs.
Frontiers Apr 23, 2026
Narrative review outlines clinical framework for managing primary Sjögren's disease with interstitial lung disease
Gastroenterology RCT
Narrative review outlines clinical framework for managing primary Sjögren's disease with interstitial lung disease New Hope for Sjögren's Patients with Lung Scarring
A narrative review synthesizes evidence on managing primary Sjögren's disease with interstitial lung disease, highlighting a pragmatic clini…
Lung scarring in Sjögren's disease can be deadly, but new strategies targeting specific disease patterns offer a path forward for patients.
Frontiers Apr 15, 2026
Physical activity improves cardiopulmonary function and general health in individuals with Sjögren's syndrome
Nephrology Meta-analysis
Physical activity improves cardiopulmonary function and general health in individuals with Sjögren's syndrome Physical activity linked to better health and function in Sjögren's syndrome patients
This systematic review and meta-analysis of randomized controlled trials evaluated physical activity versus controls in 277 participants wit…
For people with Sjögren's syndrome, physical activity improves heart and lung function, energy, and mental health, though it does not clearl…
Frontiers Apr 13, 2026
Reduced anti-CXCR3 antibodies associated with systemic autoimmunity and atherosclerosis in cohort study
Rheumatology Cohort
Reduced anti-CXCR3 antibodies associated with systemic autoimmunity and atherosclerosis in cohort study Study finds link between specific antibody levels and heart disease risk in autoimmune conditions
An observational cohort study of patients with rheumatoid arthritis, Sjogren disease, and controls found reduced anti-CXCR3 antibody levels …
Low levels of a specific antibody in early arthritis and joint pain are linked to higher heart disease risk and poorer medication responses.
medRxiv Apr 4, 2026
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case
Diabetes & Endocrinology Sys. Review
Rituximab with prednisone reduced proteinuria in Sjögren's syndrome-associated membranous nephropathy case Rituximab treatment reduced kidney protein loss in one Sjögren's syndrome patient
A case report describes a 48-year-old female with primary Sjögren's syndrome and nephrotic-range proteinuria treated with prednisone and rit…
A 48-year-old woman with Sjögren's syndrome saw her kidney protein loss drop from 8.5 to 2.2 grams after receiving rituximab treatment.
Frontiers Apr 3, 2026

Questions about Sjogren's Syndrome

Can prednisone and rituximab treat kidney issues in Primary Sjogren's Syndrome?

Yes, a case report shows that using prednisone and rituximab together reduced proteinuria in a patient with kidney issues caused by Primary Sjogren's Syndrome.

Full answer →
Can RNA methylation changes explain my Primary Sjogren's Syndrome symptoms?

RNA methylation changes are a known biological mechanism that helps explain the inflammation and tissue damage seen in Primary Sjogren's Syndrome, though they are not the only cause of your specific symptoms.

Full answer →
Can stem cell therapy help treat dry eye in Sjogren's syndrome?

Early evidence suggests stem cell therapy, including eye drops and exosomes, may improve dry eye symptoms in Sjögren's syndrome, but more research is needed before it becomes a standard treatment.

Full answer →